SCHEMBL30730481

SCHEMBL30730481

Cc1nonc1CC(=O)N1CCC(c2nnn(-c3ccc(F)cc3)n2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
CPT1A P50416 1/20 0.42
LMNA P02545 4/20 0.41
PKM P14618 2/20 0.41
ALDH1A1 P00352 4/20 0.40
GFER P55789 1/20 0.40
TSHR P16473 3/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
POLB P06746 2/20 0.38
RORC P51449 1/20 0.36
MAPT P10636 2/20 0.36
ALOX12 P18054 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730486 0.79 KMT2A (0.45) KMT2ALMNAPKMALDH1A1GFER
SCHEMBL30730482 0.78 LMNA (0.48) KMT2ALMNAPKMALDH1A1GFER
SCHEMBL30730606 0.77 PKM (0.41) KMT2ALMNAPKMALDH1A1GFER
SCHEMBL30730513 0.77 LMNA (0.48) KMT2ALMNAPKMALDH1A1GFER
SCHEMBL30730510 0.76 TNKS (0.50) LMNAPKMALDH1A1TSHRALOX15
SCHEMBL30730484 0.75 LMNA (0.49) KMT2ALMNAPKMALDH1A1GFER
SCHEMBL30730585 0.75 LMNA (0.47) KMT2ALMNAPKMALDH1A1GFER
SCHEMBL32677083 0.75 PKM (0.42) KMT2ALMNAPKMALDH1A1GFER
SCHEMBL30730691 0.74 LMNA (0.46) KMT2ALMNAPKMALDH1A1GFER
SCHEMBL30730690 0.74 LMNA (0.46) KMT2ALMNAPKMALDH1A1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 KMT2A 4715/4885CPT1A 227/4885LMNA 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.